Chinyere I Ogbonna, MD, MPH
Psychiatry · San Jose
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 4
- 1 carrier
- Office
- 1
Offices
1 location
Plans that list them
4 plans · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Ogbonna’s office at (408) 261-7777 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| Kaiser Permanente Dual Complete North P2 (HMO D-SNP) | Kaiser Permanente | Listed | Sep 1, 2026 |
| Kaiser Permanente Dual Complete North P23 (HMO D-SNP) | Kaiser Permanente | Listed | Sep 1, 2026 |
| Kaiser Permanente Sr Adv Basic Santa Clara (HMO) | Kaiser Permanente | Listed | Sep 1, 2026 |
| Kaiser Permanente Sr Adv Enhanced Santa Clara (HMO) | Kaiser Permanente | Listed | Sep 1, 2026 |
California Medical Board record
Licence A133953 · Current
Licensed to practise in California · since 2014 · expires 2028-08-31 · Temple University School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Drugs they prescribed that Part D paid
$2,793
Pharmacies billed $2,793 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 129) in 2024. At or below the middle of the specialty; the typical psychiatry & neurology clinician is at 0%.
129 generic and 0 brand-name prescriptions · $2,793 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Buprenorphine-Naloxone | 43 | $1,281 | $30 |
| Hydroxyzine | 16 | $204 | $13 |
Year by year
| 2024 | 129 | 13 | 0% (0) | 0% | $2,793 |
| 2023 | 139 | 14 | None | 0% | $3,220 |
| 2022 | 192 | 21 | 0% (0) | 0% | $9,062 |
| 2021 | 220 | 21 | 0% (0) | 0% | $9,765 |
| 2020 | 259 | 28 | None | None | $11,616 |
| 2019 | 274 | 31 | None | 0% | $9,816 |
| 2018 | 259 | 26 | None | None | $20,350 |
| 2017 | 114 | 26 | None | None | $3,631 |
| 2016 | 230 | 33 | None | 9% | $18,517 |
| 2015 | 218 | 44 | None | 30% | $19,214 |
| 2014 | 352 | 46 | None | 24% | $40,974 |
| 2013 | 357 | 50 | 5% (17) | None | $26,438 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 3 drugs
| Buprenorphine-Naloxone | 41 | $1,421 | $35 |
| Hydroxyzine | 15 | $150 | $10 |
| Trazodone | 12 | $121 | $10 |
2022: 5 drugs
| Buprenorphine-Naloxone | 78 | $4,502 | $58 |
| Gabapentin | 23 | $506 | $22 |
| Sertraline | 11 | $134 | $12 |
| Hydroxyzine | 13 | $131 | $10 |
| Escitalopram | 11 | $104 | $9 |
2021: 4 drugs
| Buprenorphine-Naloxone | 113 | $6,459 | $57 |
| Gabapentin | 34 | $586 | $17 |
| Sertraline | 15 | $186 | $12 |
| Hydroxyzine | 12 | $124 | $10 |
2020: 5 drugs
| Buprenorphine-Naloxone | 114 | $8,651 | $76 |
| Naltrexone | 14 | $866 | $62 |
| Gabapentin | 28 | $570 | $20 |
| Sertraline | 15 | $168 | $11 |
| Hydroxyzine | 15 | $165 | $11 |
2019: 7 drugs
| Buprenorphine-Naloxone | 115 | $7,642 | $66 |
| Naltrexone | 18 | $611 | $34 |
| Gabapentin | 31 | $369 | $12 |
| Hydroxyzine | 16 | $150 | $9 |
| Sertraline | 13 | $127 | $10 |
| Citalopram Hbr | 15 | $115 | $8 |
| Trazodone | 12 | $93 | $8 |
2018: 4 drugs
| Buprenorphine-Naloxone | 152 | $17,893 | $118 |
| Clonidine | 18 | $583 | $32 |
| Naltrexone | 14 | $483 | $35 |
| Gabapentin | 18 | $236 | $13 |
2017: 3 drugs
| Buprenorphine-Naloxone | 20 | $1,729 | $86 |
| Trazodone | 21 | $230 | $11 |
| Gabapentin | 12 | $203 | $17 |
2016: 5 drugs
| Buprenorphine-Naloxone | 27 | $5,072 | $188 |
| Haloperidol | 14 | $768 | $55 |
| Lisinopril | 41 | $238 | $6 |
| Gabapentin | 11 | $134 | $12 |
| Benztropine Mesylate | 11 | $112 | $10 |
2015: 2 drugs
| Suboxone | 14 | $3,734 | $267 |
| Lisinopril | 14 | $124 | $9 |
2014: 7 drugs
| Abilify | 24 | $19,647 | $819 |
| Quetiapine | 15 | $838 | $56 |
| Bupropion Xl | 15 | $418 | $28 |
| Sertraline | 12 | $120 | $10 |
| Lisinopril | 19 | $98 | $5 |
| Clonazepam | 19 | $98 | $5 |
| Trazodone | 15 | $90 | $6 |
2013: 5 drugs
| Abilify | 15 | $11,216 | $748 |
| Levothyroxine | 18 | $201 | $11 |
| Furosemide | 17 | $105 | $6 |
| Carvedilol | 11 | $103 | $9 |
| Amlodipine Besylate | 11 | $82 | $7 |
Money from drug and device companies
$14 in 2023
| 2023 | 1 | 1 | None | $14 |
| 2022 | 1 | 1 | None | $21 |
| 2019 | 1 | 1 | $125 | $125 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Neurocrine Biosciences | Ingrezza | $14 | 1 payment
|
See the published payment
| Neurocrine Biosciences | Meals · 2023-08-02 | Ingrezza | $14 |
See earlier years (2022, 2019)
2022: $21
| Novo Nordisk | Saxenda | $21 | 1 payment
|
2019: $125
| Titan Pharmaceuticals | Probuphine | $125 | 1 payment
|
Professional record
- NPI
- 1730405770
- Licence
- CA A133953California A133953: Current · expires 2028-08-31
More record details
- Sole proprietor
- Yes
- Taxonomy
- Psychiatry (2084P0800X); Family medicine (207Q00000X)
- Mailing address
- 401 Quarry Rd, Stanford, CA, 94305
- NPI first listed
- 2010-04-15
- NPI last updated
- 2022-02-11
This is when the NPI record was last certified, not a medical board exam.
This office lists an electronic records connection.